• On February 25, 2026, Recursion Pharmaceuticals reported full-year 2025 results showing revenue of US$74.68 million, a net loss of US$644.76 million, and simultaneously filed a US$300 million at-the-market follow-on offering plus a US$68.57 million shelf registration for 19,424,000 Class A shares tied to employee plans.
• Alongside beating fourth-quarter loss and revenue expectations, management stated that cost controls and partnerships have extended Recursion’s cash runway into early 2028 while advancing its REC-4881 program and broader AI-enabled pipeline.
• We’ll now examine how the extended cash runway into early 2028 may influence Recursion Pharmaceuticals’ existing investment narrative and risk profile.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Recursion Pharmaceuticals Investment Narrative Recap

To own Recursion, you have to believe its AI-enabled platform can turn large R&D spend and early-stage programs into clinically meaningful drugs and partnership value. The latest update modestly de-risks funding by extending the cash runway into early 2028, but it does not change the near term focus on clinical progress for REC-4881 as the key catalyst, nor does it remove the central risk of continued heavy losses and dependence on external capital and partner milestones.

The US$300 million at the market follow-on offering filing is the most relevant piece of news here, because it sits directly beside the company’s updated runway guidance. Together, they highlight how Recursion is pairing cost controls and partnerships with the option to raise equity as needed while moving REC-4881 and its broader AI-driven pipeline forward. For investors tracking upcoming regulatory interactions and early stage readouts, this financing overhang now becomes part of the short term story.

Yet, even with a longer runway, the risk that high cash burn and fresh dilution pressure existing shareholders is something investors should be very aware of...

Recursion Pharmaceuticals’ narrative projects $220.9 million revenue and $35.5 million earnings by 2028. This requires 50.7% yearly revenue growth and a roughly $684.6 million earnings increase from -$649.1 million today.

Uncover how Recursion Pharmaceuticals' forecasts yield a $7.00 fair value, a 86% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming Recursion’s revenue would reach only about US$102 million by 2028 and remain unprofitable, which is far more pessimistic than the consensus view of platform driven milestones and a longer cash runway; as this new US$644.76 million loss and fresh ATM capacity sink in, you may find that these more cautious expectations around ongoing cash burn and dilution risk start to look either too harsh or not harsh enough.

Explore 6 other fair value estimates on Recursion Pharmaceuticals - why the stock might be worth 48% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Recursion Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 53 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.